HTG to Spend $16M in New Financing to Develop Tests, Hire More Staff
June 21, 2011
HTG to Spend $16M in New Financing to Develop Tests, Hire More Staff
HTG aims to boost adoption of its multiplex gene expression-testing platform in three business areas: molecular testing for translational medicine, pharmaceutical clinical development, and clinical pathology diagnostics.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Q&A: INMEGEN's Alfredo Hidalgo on Using Genomics to Address Mexico's Most Pressing Health Problems
May 17, 2013 / BioArray News - Aiming at '$12B Opportunity,' Illumina to Expand Sales Presence, Invest in Reproductive Health
May 14, 2013 / BioArray News - Despite Continued Genotyping Growth, Weak Expression Sales Force Affymetrix to Suspend Guidance
May 7, 2013 / BioArray News - Q&A: Baylor's Federico Monzon on Microarrays, Sequencing, and Cancer Cytogenetics
May 7, 2013 / BioArray News - Q&A: Kuwait University's Fahd Al-Mulla on Genome Arabia and Genomics in the Middle East
April 30, 2013 / BioArray News